daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4953	152923-56-3

Description:

Molecule	Description
Synonyms: zinbryta daclizumab zenapax	An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

zinbryta
daclizumab
zenapax

An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
5	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 26, 1999	EMA
Dec. 10, 1997	FDA	HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2432.68	47.43	405	4584	4467	63479566
Transplant rejection	1931.24	47.43	376	4613	10404	63473629
Ovarian cyst	1715.25	47.43	364	4625	15581	63468452
Acne	1593.95	47.43	367	4622	22926	63461107
Alopecia	777.00	47.43	418	4571	337118	63146915
Liver function test abnormal	411.56	47.43	151	4838	48030	63436003
Sleep disorder due to general medical condition, insomnia type	374.44	47.43	144	4845	52073	63431960
Multiple sclerosis relapse	281.92	47.43	115	4874	48363	63435670
Rheumatoid arthritis	180.47	47.43	153	4836	253666	63230367
Pneumonia	141.72	47.43	176	4813	456591	63027442
Condition aggravated	123.00	47.43	154	4835	402063	63081970
Loss of personal independence in daily activities	111.31	47.43	78	4911	97212	63386821
Overdose	95.28	47.43	76	4913	115002	63369031
Kidney transplant rejection	91.87	47.43	27	4962	4244	63479789
Incorrect route of product administration	88.00	47.43	43	4946	27409	63456624
Pain	78.38	47.43	176	4813	740452	62743581
Product use issue	55.53	47.43	77	4912	220443	63263590

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple sclerosis relapse	148.33	37.54	36	558	13097	34943240

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Transplant dysfunction	2373.37	43.52	408	4736	6813	79732431
Ovarian cyst	1876.56	43.52	365	4779	12290	79726954
Transplant rejection	1766.41	43.52	373	4771	19064	79720180
Acne	1609.11	43.52	367	4777	26823	79712421
Alopecia	999.37	43.52	416	4728	230939	79508305
Sleep disorder due to general medical condition, insomnia type	427.66	43.52	144	5000	43412	79695832
Liver function test abnormal	401.29	43.52	152	4992	64323	79674921
Multiple sclerosis relapse	319.54	43.52	118	5026	46415	79692829
Rheumatoid arthritis	231.95	43.52	152	4992	208318	79530926
Condition aggravated	124.98	43.52	157	4987	500967	79238277
Pneumonia	122.43	43.52	179	4965	660067	79079177
Loss of personal independence in daily activities	121.55	43.52	78	5066	102502	79636742
Pain	104.09	43.52	172	4972	703630	79035614
Incorrect route of product administration	86.22	43.52	43	5101	34886	79704358
Overdose	84.89	43.52	80	5064	184126	79555118
Product use issue	76.11	43.52	80	5064	209742	79529502
Drug ineffective	60.68	43.52	179	4965	1080734	78658510
Encephalitis autoimmune	49.86	43.52	14	5130	2280	79736964

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA MoA	N0000010279	Interleukin 2 Receptor Antagonists
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
FDA MoA	N0000175621	Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC	N0000175622	Interleukin-2 Receptor Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal transplant rejection	indication	236570004
Relapsing remitting multiple sclerosis	indication	426373005	DOID:2378

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-2 receptor	Membrane receptor	P01589 P14784 P31785	IL2RA_HUMAN IL2RB_HUMAN IL2RG_HUMAN	ANTIBODY BINDING	Kd	8		IUPHAR	DRUG LABEL

External reference:

ID	Source
D03639	KEGG_DRUG
4021083	VUID
N0000148541	NUI
4021083	VANDF
CHEMBL1201605	ChEMBL_ID
6880	IUPHAR_LIGAND_ID
DB00111	DRUGBANK_ID
1795335	RXNORM
11508	MMSL
241453	MMSL
4529	MMSL
d04262	MMSL
007284	NDDF
109133001	SNOMEDCT_US
386977009	SNOMEDCT_US
C0663182	UMLSCUI
D000077561	MESH_DESCRIPTOR_UI
7164	INN_ID
CUJ2MVI71Y	UNII

Pharmaceutical products:

None